New England Surgical Society (NESS)
Search NESS
  Home
  Annual Meeting
  Annual Resident and Fellow Research Day
  Members
      Member Directory
      Members Only
  Scholars Foundation
  Job Board
  Awards
  Journal of the American College of Surgeons
  Newsletters
  Committees
  Contact NESS

2010 Annual Meeting Abstracts

Back to Program


MicroRNA-222 Modulates Tamoxifen Resistance In Papillary Thyroid Cancer
Hyunsuk Suh, Susana Wishinia, *Susannah Orzell, *Samuel Kim, *Frances Tangherlini, *Samir Sur, *Stephanie Lee, Jennifer E Rosen
Boston University, Boston, MA

Objective
• Establish baseline sensitivity of papillary thyroid cancer cell line BCPAP and breast cancer cell line MCF7.
• Correlate the miR222 level and their effect on Tamoxifen sensitivity by manipulating miR222 level.

Design
• Basic science experiment
Setting
• Academic institution.

Patients
• None.

Interventions
• Tamoxifen treatment to ER+ BCPAP and MCF7
• Transfection of above cell lines with antimiR222, premiR222 and negative control scramble RNA to modulate the level of miR222.
•Tamoxifen treatments.

Main Outcome Measures:
• Proliferation assays
• Apoptosis assays

Results
• MCF7 and BCPAP cells show similar baseline sensitivity to Tamoxifen (P < 0.01)
• Decreasing the level of miR222 (via antimiR222 transfection) increased sensitivity of Tamoxifen in both BCPAP and MCF7 cell lines in respect to the control group (P < 0.05).
• Increasing the level of miR222 (via premiR222 transfection) induced Tamoxifen resistance in respect to the control group.
• Tamoxifen induced apoptosis in MCF7 and BCPAP cells.

Conclusions
• BCPAP cells display near identical sensitivity and mechanism of resistance to Tamoxifen to that of breast cancer cells. Single transfection of miR222 modulating agents can alter the sensitivity to Tamoxifen.
• miR222 may have its role via the estrogen receptors and subsequent apoptotic pathway
• Estrogen may play an importance role in thyroid cancer, and anti-estrogen drugs may provide a new therapeutic treatment option for thyroid cancers


Back to Program

 

Copyright © 2018 New England Surgical Society. All Rights Reserved.
Read Privacy Policy.